KRP330
干扰素α/β受体2, Interferon alpha/beta receptor 2 , IFN-R-2, IFN-alpha binding protein, IFN-alpha/beta receptor 2, Interferon alpha binding protein, Type I interferon receptor 2, IFNABR, IFNARB, Interferon alpha/beta receptor 2, IFN-R-2,
| Alias | 干扰素α/β受体2, Interferon alpha/beta receptor 2 , IFN-R-2, IFN-alpha binding protein, IFN-alpha/beta receptor 2, Interferon alpha binding protein, Type I interferon receptor 2, IFNABR, IFNARB, Interferon alpha/beta receptor 2, IFN-R-2, |
| Catalog Number | KRP330 |
| Molecular Name | IFNAR2 |
| Molecular Weight | 66-90 kDa |
| Size | 20ug, 50ug, 100ug, 200ug, 1mg |
| Concentration | 联系销售经理获得最新批次的浓度 |
| Purity | ≥95% |
| SDS-PAGE |  |
| Product Description | Human IFNAR2(27-243 aa) |
| Storage Condition | Store the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -20℃. Avoid repeated freeze-thaw cycles. |
| Formulation | < 0.1 EU per ug |
| Shipping Condition | This product is shipped on ice packs or dry ice. |
| Background | Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) (PubMed:10049744, PubMed:10556041, PubMed:21854986, PubMed:26424569, PubMed:28165510, PubMed:32972995, PubMed:7665574, PubMed:7759950, PubMed:8181059, PubMed:8798579, PubMed:8969169). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response (PubMed:10049744, PubMed:17517919, PubMed:21854986, PubMed:26424569, PubMed:28165510, PubMed:32972995, PubMed:7665574, PubMed:7759950, PubMed:8181059, PubMed:8798579, PubMed:8969169). Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another (PubMed:10556041, PubMed:11682488, PubMed:12105218, PubMed:21854986, PubMed:32972995). The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (STAT1, STAT2 and STAT) (PubMed:11682488, PubMed:12105218, PubMed:21854986, PubMed:32972995). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes (PubMed:12105218, PubMed:28165510, PubMed:9121453). {ECO:0000269|PubMed:10049744, ECO:0000269|PubMed:10556041, ECO:0000269|PubMed:11682488, ECO:0000269|PubMed:12105218, ECO:0000269|PubMed:17517919, ECO:0000269|PubMed:21854986, ECO:0000269|PubMed:26424569, ECO:0000269|PubMed:28165510, ECO:0000269|PubMed:32972995, ECO:0000269|PubMed:7665574, ECO:0000269|PubMed:7759950, ECO:0000269|PubMed:8181059, ECO:0000269|PubMed:8798579, ECO:0000269|PubMed:8969169, ECO:0000269|PubMed:9121453}.; [Isoform 3]: Potent inhibitor of type I IFN receptor activity. {ECO:0000269|PubMed:7759950}. |
| Species | Human |
| Purification | Affinity Purification |
| Endotoxin | Supplied in PBS |
| Biological Activity | Immobilized recombinant Human IFNA2 at 2 μg/mL (100 μL/well) can bind Human IFNAR2 with a linear range of 0.2-617 ng/mL. |
| Uniprot ID | P48551-1 |
| Product Declaration | 该产品仅供科研使用，不可直接用于人体或注射。 |
| Display Peptides | HEK293F Cells |
销售微信
官方公众号
0
